In vivo studies demonstrate that L-PC was able to significantly lower blood pressure in CyA treated animals and to prevent decrease creatinine clearance that normally results from CyA administration [57]
If you look at the post-approval withdrawal of anti-obesity drugs, pulled from the market because of safety concerns only discovered years later, it took an average of a decade before dangers came to light
We could also outline a parallel case study on Eli Lillys similar experience with shortages of Tirzepatide (Mounjaro / Zepbound), overcome by a flexible (and growing) manufacturing base
We went through several different rounds
While most peptides benefit from dark storage, copper peptides actively degrade under light exposure through photocatalyzed oxidation reactions
Akbari, M., Larijani, B., & Sohrab, G